Clinlab.AI will oversee every aspect of this new-look laboratory, working to integrate it with the practice's workflows in a way that boosts patient care and speeds up treatment decisions.
More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
Hemodynamic valve deterioration after one year was more common in patients with a small aortic annulus. In fact, receiving a larger valve was linked to a “protective” quality that appeared to help keep the risk of such complications to a minimum.
New ACC/AHA recommendations encourage clinicians to take a proactive approach when managing patients with elevated or high blood pressure. The inclusion of renal denervation in this document represents clear progress for a relatively new technology.
The FDA has received multiple reports of the devices, which are designed to be malleable, failing to retain their shape. The issue has been linked to three patient injuries so far, and customers are asked to return unused devices to the manufacturer.
“Our findings reveal how changes in cell metabolism and increased oxidative stress can activate damaging pathways in blood vessels," explained Xiaofeng Yang, MD, a researcher at Temple University.
